scorecardresearch
Tuesday, August 5, 2025
Support Our Journalism
HomeIndiaIndia-based Hetero's Paxlovid generic gets WHO backing

India-based Hetero’s Paxlovid generic gets WHO backing

Follow Us :
Text Size:

(Reuters) – India’s Hetero said on Tuesday that its generic version of Paxlovid, an antiviral treatment for COVID-19 developed by Pfizer Inc, was added to the World Health Organization’s prequalification list, which serves as a benchmark for procurement of medicines by developing countries.

Hetero said it had entered into a licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) to manufacture and sell the generic version of the drug in low- and middle-income countries.

The treatment bundles two nirmatrelvir pills and one ritonavir pill and will be manufactured at Hetero’s plants in India, where the drug has emergency use authorization from the country’s drugs controller general.

The global health agency has strongly recommended the use of Pfizer’s Paxlovid for treating high-risk patients with mild and moderate COVID, while expressing concerns regarding its access in low- and middle-income countries.

(Reporting by Bhanvi Satija in Bengaluru; Editing by Shailesh Kuber and Anil D’Silva)

Disclaimer: This report is auto generated from the Reuters news service. ThePrint holds no responsibilty for its content.

Subscribe to our channels on YouTube, Telegram & WhatsApp

Support Our Journalism

India needs fair, non-hyphenated and questioning journalism, packed with on-ground reporting. ThePrint – with exceptional reporters, columnists and editors – is doing just that.

Sustaining this needs support from wonderful readers like you.

Whether you live in India or overseas, you can take a paid subscription by clicking here.

Support Our Journalism

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular